Back to Search
Start Over
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.
- Source :
- Medicine; 5/22/2020, Vol. 99 Issue 21, p1-8, 8p
- Publication Year :
- 2020
Details
- Language :
- English
- ISSN :
- 00257974
- Volume :
- 99
- Issue :
- 21
- Database :
- Complementary Index
- Journal :
- Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 144330954
- Full Text :
- https://doi.org/10.1097/MD.0000000000019883